Tislelizumab Improves OS Compared With Chemo in Advanced Unresectable or Metastatic ESCC
In patients with advanced or metastatic esophageal squamous cell carcinoma, treatment with the anti‑PD‑1 antibody tislelizumab significantly improves overall survival compared with investigator‑chosen chemotherapy
The phase 3 RATIONALE 302 trial demonstrated that compared to chemotherapy, tislelizumab showed a statistically significant and clinically meaningful improvement in overall survival in the intention‑to‑treat population of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Esophageal cancer has a high mortality rate and limited treatment options; a therapy that improves overall survival represents a major advance in patient care.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT